Business
Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022
Recursion initiates TUPELO, a Phase 2 trial of REC-4881 for the potential treatment of Familial Adenomatous Polyposis (FAP)Recursion initiates a Phase 1 trial
About this update from Recursion Pharmaceuticals, Inc.
[{"type":"text","content":"Recursion initiates TUPELO, a Phase 2 trial of REC-4881 for the potential treatment of Familial Adenomatous Polyposis (FAP)Recursion initiates a Phase 1 trial for the potential treatment of Clostridium difficile (C. diff) Colitis with Recursion's first new chemical entity to enter the clinicSALT LAKE CITY, Sept. 13, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the initiation of two additional clinical trials including its first in-house generated new chemical entity to enter the clinic. Recursion has now initiated a total of four clinical trials in 2022; three Phase 2 or 2/3 proof-of-concept studies and one Phase 1 study.\n\n \n \n \n \n \n \n\n \n\"In a challenging year for the biotech industry, Recursion has continued to deliver on its goals and mission to decode biology to radically improve lives,\" said Chris Gibson, Ph.D., CEO and Co-Founder of Recursion. \"Our teams have worked tirelessly to advance our first new chemical entity into a first-in-human study and deliver on our goals, initiating four new clinical trials this year. These include initiating a Phase 2 trial for cerebral cavernous malformation (CCM) in March, a Phase 2/3 trial for neurofibromatosis type 2 (NF2)-mutated meningiomas in June, and now our Phase 2 trial for FAP and Phase 1 trial for C. diff.\"\nAbout the Phase 2 Trial of REC-4881 for FAP\nThe Phase 2 TUPELO clinical trial is evaluating REC-4881 for the potential treatment of familial adenomatous polyposis (FAP) in patients who have previously undergone a colectomy/proctocolectomy. REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce polyp burden and progression to adenocarcinoma in people living with FAP. It has been granted Fast Track and Orphan Drug designations for the potential treatment of FAP by the U.S. Food and Drug Administration as well as Orphan Drug designation by the European Commission.\nThere are currently no FDA-approved therapies for the treatment of FAP, a rare tumor predisposition syndrome affecting approximately 50,000 people in the US, France, Germany, Italy, Spain and the UK. Recursion discovered REC-4881 as a potential candidate for treatment of FAP by leveraging its proprietary AI-powered...